MTOR and renal cell carcinoma: Current RCC treatment relies primarily on tyrosine kinase inhibitors (sunitinib, pazopanib), immune checkpoint inhibitors (nivolumab, pembrolizumab), and mTOR inhibitors (everolimus, temsirolimus).